§ BIOTECHNOLOGY
USD · BiotechnologyFATE
FATE THERAPEUTICS INC
USDSector · Biotechnology
§ 01 · PRICE
Price action
1D5D1M6MYTD1YMAX
§ 03 · SIGNAL STACK · WHAT THE INPUTS SAY
13F FLOW
92 increased/new, 38 decreased/exited (13F)
AC 13F Analysis
§ 05 · WHO OWNS IT
Top institutional holders
| Fund | Shares | % port | Δ Q/Q |
|---|---|---|---|
| Redmile Group, LLC | 12.9M | 1.0% | ±0% |
| BlackRock, Inc. | 10.1M | 0.0% | −1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2M | n/a | n/a |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.1M | n/a | n/a |
| TWO SIGMA INVESTMENTS, LP | 3.5M | 0.0% | +100% |
| JOHNSON & JOHNSON | 3.4M | 0.6% | n/a |
◇ AC INTELLIGENCE
Top institutional owners for FATE as of the most recent 13F reporting period (Q1 2026 · Period ended Mar 31). Δ Q/Q reflects share-count change vs. the prior filing — positive green means adding, negative red means trimming. Cross-reference with the ownership-mix bars below to see which strategy cohort is driving the flow.
§ 06 · WHO OWNS IT · BY STRATEGY
OTHER32.3% · 0 holders
OTHER43.7% · 108 holders
PASSIVE / INDEX12.1% · 9 holders
DEALER / BANK6.8% · 18 holders
SYSTEMATIC / QUANT2.7% · 3 holders
QUALITY / COMPOUNDER1.3% · 9 holders
TACTICAL / MACRO0.8% · 1 holder
INCOME / DEFENSIVE0.2% · 7 holders
◇ AC INTELLIGENCE
Ownership mix by behavioral cohort. Top bars indicate which style of capital dominates the float — passive indexing, quality compounders, dealer/bank, systematic quant, etc. Big quality-compounder share means concentrated active conviction; heavy passive share means flows are dictated by index rebalances, not fundamentals.
§ 07 · INSIDER ACTIVITY · LAST 180 DAYS
NO INSIDER FILINGS
◇ AC INTELLIGENCE
No Form 4 filings on record for FATE in the last 180 days.